HOME >> MEDICINE >> NEWS
Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy

Late-breaking presentation shows multilineage blood cell growth with excellent safety in chemotherapy patients

Maret Pharmaceuticals, Inc. today reported positive Phase I/II clinical results that demonstrate the potential of MARstem™ as a multilineage hematopoietic therapy (multiple blood cell stimulant) to treat or prevent pancytopenia (a reduction in different types of blood cells) following chemotherapy in breast cancer patients. The study was selected as a late breaking abstract at the 11th National Cancer Institute - European Organization for Research and Treatment of Cancer - American Association for Cancer Research (NCI-EORTC-AACR) Symposium on New Drugs in Cancer Therapy.

The study was designed to evaluate safety, optimal dose and proof-of-principle efficacy of MARstem in adjuvant breast cancer patients. The results show that MARstem reduced the frequency of grade 2-4 thrombocytopenia (decrease in the number of blood platelets), grade 2-4 anemia (deficiency in red blood cells), and grade 3-4 lymphopenia (reduction in the number of lymphocytes) as compared to controls.

"These early clinical results suggest that MARstem may effective in improving or reducing the debilitating side effects of cancer treatment," said Terry Winters, Ph.D., Chairman and Chief Executive Officer of Maret Pharmaceuticals. MARstem has a clear therapeutic benefit as a multilineage hematopoietic factor as compared to traditional hematopoietic stimulants, which selectively increase only a single blood cell line. The trials outcome is promising, as the safety of MARstem has been established and the preliminary efficacy results are encouraging.

The studys results suggest that MARstem exhibits an excellent safety profile. There were no dose-limiting toxicities in the patients treated with MARstem. Specifically, there were no adverse cardiovascular or hematologic effects. The overall occurrence of side effects was lower in MARstem pa
'"/>

Contact: Heather Rosoff
hrosoff@fkhealth.com
617-761-6770
Feinstein Kean Healthcare
9-Nov-2000


Page: 1 2

Related medicine news :

1. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
2. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
3. NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
4. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
5. Pharmaceuticals and personal care products
6. Nortran Pharmaceuticals Inc. and Hoechst Marion Roussel announce collaborativeagreement
7. Signal Pharmaceuticals Announces Positive Results In Preclinical Study Of Novel Drug Leads For Treatment Of Osteoporosis
8. Beyond Pharmaceuticals: Business And Academic Leaders Forecast The Future Of "Combinatorial Chemistry"
9. ONYX Pharmaceuticals Reports Phase II Clinical Trial Results At ASCO Meeting
10. American Academy of Neurology presents 57th Annual Meeting in Miami Beach
11. Hard choices: Pitt researcher presents findings on when to accept organ transplants

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/12/2018)... ... , ... Donaldson Plastic Surgery has been included on the Inc. 5000 list ... list of central Ohio's fastest growing businesses. The plastic surgery practice was ranked number ... is the only medical practice and plastic surgery office to make the regional Fast ...
(Date:9/7/2018)... ... September 07, 2018 , ... The Ramsey Keller ... its first-ever national retreat for moms who are living without a child. “ The ... weekend of October 26, 27 and 28 at Fairmont Hot Springs Resort ...
(Date:9/1/2018)... ... August 31, 2018 , ... SignatureCare Emergency Center is looking to ... Fall semester to a deserving student. Get your applications in now as the deadline ... to Hanna Wu who is a medical student at Texas Southern University. Wu was ...
(Date:8/31/2018)... EAST HANOVER (PRWEB) , ... August 31, 2018 ... ... has expanded its neuroimaging capabilities with the addition of an MRI Simulator. In ... imaging (MRI) scan including sounds. By engaging in this mock scan experience, research ...
(Date:8/31/2018)... ... August 31, 2018 , ... NJ Top Docs proudly presents ... Dr. Savon has been active in gastrointestinal research for many years while South ... gastrointestinal diseases and disorders for the past 25 years. , Recently, Dr. Savon ...
Breaking Medicine News(10 mins):
(Date:9/3/2018)... ... 2018 , ... According to ACGME, the state of South ... 200 fellows for the 2018-2019 academic year. The 64 specialty programs and 63 ... as McLeod Health, MUSC Health, Tidelands Health and Tenet Healthcare will be exhibiting ...
(Date:9/1/2018)... ... 2018 , ... Dr. Payam Bostani is now offering Periodontal Osseous (bone) surgeries ... offering patients for twenty years at his Burbank offices. “My goal has always ... need under a single roof. Periodontics is a crucial specialty because our gums are ...
(Date:8/31/2018)... ... August 31, 2018 , ... The summertime sweat that many people dread is ... condition known as hyperhidrosis. In Grand Rapids , Dr. Brad Bengtson recognized the ... alike frequently soak through their shirts for no reason other than the fact that ...
Breaking Medicine Technology:
Cached News: